FDA starts NGAL Test application review process

BioPorto (CPH:BIOPOR) announced that US FDA has started to review BioPorto’s application for approval of The NGAL Test™ for the diagnosis of acute kidney injury. The NGAL Test is approved for diagnostic use in the European Union and Canada. BioPorto’s NGAL ELISA is currently the only NGAL test on the American market for the diagnosis of acute kidney injury. NGAL Test builds on this in a more user-friendly manner and it works on existing laboratory equipment.